Novartis ends mid — stage Fabhalta trial targeting serious kidney condition
Oct 16 (Reuters) — Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry. The trial was evaluating whether the oral medication was safe and effective for treating